Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Sales (2016 - 2025)

Karyopharm Therapeutics' Return on Sales history spans 14 years, with the latest figure at 2.65% for Q4 2025.

  • For Q4 2025, Return on Sales rose 366.0% year-over-year to 2.65%; the TTM value through Dec 2025 reached 0.03%, up 50.0%, while the annual FY2025 figure was 0.03%, 50.0% up from the prior year.
  • Return on Sales reached 2.65% in Q4 2025 per KPTI's latest filing, up from 0.75% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 3.0% in Q4 2023 to a low of 2.47% in Q1 2021.
  • Average Return on Sales over 5 years is 0.6%, with a median of 0.92% recorded in 2023.
  • Peak YoY movement for Return on Sales: skyrocketed 415bps in 2023, then crashed -401bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 0.54% in 2021, then crashed by -311bps to 1.15% in 2022, then soared by 361bps to 3.0% in 2023, then plummeted by -134bps to 1.01% in 2024, then skyrocketed by 362bps to 2.65% in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Return on Sales are 2.65% (Q4 2025), 0.75% (Q3 2025), and 0.98% (Q2 2025).